Literature DB >> 4114148

Cutaneous responses to human C 3 anaphylatoxin in man.

K D Wuepper, V A Bokisch, H J Müller-Eberhard, R B Stoughton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4114148      PMCID: PMC1553684     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  7 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1969       Impact factor: 23.643

2.  Anaphylatoxin release from the third component of human complement by hydroxylamine.

Authors:  D B Budzko; H Müller-Eberhard
Journal:  Science       Date:  1969-08-01       Impact factor: 47.728

3.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

4.  Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man.

Authors:  I H Lepow; K Willms-Kretschmer; R A Patrick; F S Rosen
Journal:  Am J Pathol       Date:  1970-10       Impact factor: 4.307

5.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

6.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

7.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

  7 in total
  17 in total

1.  Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release.

Authors:  E S Schulman; T J Post; P M Henson; P C Giclas
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

2.  Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.

Authors:  T Kajita; T E Hugli
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

3.  Uptake of 125I-labelled C3a by cultured human endothelial cells.

Authors:  J B Denney; A R Johnson
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

Review 4.  The role of complement in phototoxic reactions.

Authors:  H Lim; I Gigli
Journal:  Springer Semin Immunopathol       Date:  1981

5.  Release of histamine from rat mast cells by the complement peptides C3a and C5a.

Authors:  A R Johnson; T E Hugli; H J Müller-Eberhard
Journal:  Immunology       Date:  1975-06       Impact factor: 7.397

6.  Studies of human C5a as a mediator of inflammation in normal human skin.

Authors:  K B Yancey; C H Hammer; L Harvath; L Renfer; M M Frank; T J Lawley
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 7.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

Review 8.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

9.  C4a: the third anaphylatoxin of the human complement system.

Authors:  J P Gorski; T E Hugli; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  Pulmonary injury induced by C3a and C5a anaphylatoxins.

Authors:  N P Stimler; T E Hugli; C M Bloor
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.